Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD

8.08

-0.09 (-1.10%)

At close: Nov 10, 2026, 4:00 PM EST

8.07

-0.01 (-0.12%)

After-hours: Nov 10, 2026, 6:45 PM EST

Iovance Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	57.93	163.08	115.69	114.89	231.73	78.23
Short-Term Investments	318.39	133.9	208.09	164.98	240.11	426.18
Cash & Short-Term Investments	376.32	296.98	323.78	279.87	471.85	504.41
Cash Growth	25.11%	-8.28%	15.69%	-40.69%	-6.46%	-19.86%
Receivables	106.99	82.45	69.34	0.15	-	-
Inventory	55.22	51.68	51.52	10.37	-	-
Prepaid Expenses	11.11	11.58	12.38	17.46	7.27	3.55
Total Current Assets	549.64	442.69	457.02	307.85	479.12	507.96
Property, Plant & Equipment	171.87	177.01	164.28	176.55	178.25	169.92
Long-Term Investments	-	-	-	-	-	91.59
Other Intangible Assets	259.21	279.32	282.4	229.26	-	-
Other Long-Term Assets	10.5	14.15	6.73	66.7	6.62	7.87
Total Assets	991.21	913.17	910.43	780.35	663.98	777.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	21.65	22.16	27.51	33.12	26.6	27.38
Accrued Expenses	78.87	104.71	75.19	66.97	45.79	51.91
Current Portion of Long-Term Debt	-	1	-	-	-	-
Current Portion of Leases	2.44	4.04	12.9	7.78	12.59	5.06
Other Current Liabilities	2.81	6.45	6.75	2.44	6.51	4.86
Total Current Liabilities	105.77	138.36	122.34	110.31	91.49	89.2
Long-Term Debt	-	-	1	1	1	1
Long-Term Leases	42.77	44.4	44.37	67.09	71.86	65.47
Long-Term Deferred Tax Liabilities	30.01	31.83	32.32	17.35	-	-
Total Liabilities	178.55	214.59	200.02	195.74	164.34	155.67

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.02	0.02	0.01	0.01	0.01	0.01
Additional Paid-In Capital	3,723	3,458	3,096	2,594	2,069	1,795
Retained Earnings	-2,924	-2,776	-2,385	-2,012	-1,568	-1,172
Comprehensive Income & Other	13.85	16.44	-1.05	2.53	-0.9	-0.6
Total Common Equity	812.66	698.58	710.4	584.61	499.64	621.66
Shareholders' Equity	812.66	698.58	710.41	584.61	499.64	621.66
Total Liabilities & Equity	991.21	913.17	910.43	780.35	663.98	777.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	45.21	49.44	58.26	75.86	85.45	71.53
Net Cash (Debt)	331.11	247.54	265.52	204.01	386.4	432.88
Net Cash Growth	33.34%	-6.77%	30.15%	-47.20%	-10.74%	-25.08%
Net Cash Per Share	0.76	0.69	0.92	0.87	2.43	2.82
Filing Date Shares Outstanding	462.66	411.96	327.88	279.31	224.24	157.17
Total Common Shares Outstanding	462.54	411.94	305.25	256.14	187.81	157
Working Capital	443.86	304.33	334.68	197.54	387.63	418.76
Book Value Per Share	1.76	1.70	2.33	2.28	2.66	3.96
Tangible Book Value	553.45	419.26	428	355.35	499.64	621.66
Tangible Book Value Per Share	1.20	1.02	1.40	1.39	2.66	3.96
Machinery	44.98	45.34	34.28	33.27	31.79	14.87
Construction In Progress	8.04	35.65	34.94	24.1	9.12	35.78
Leasehold Improvements	127.9	90.39	67.38	76.8	74.31	57.82

SEC Filings: 10-K · 10-Q